Several clinical studies have shown GLP-1 analogue liraglutide, alone or in combination with insulin, has produced meaningful long-term weight loss, diminished abdominal obesity and significantly improved eating behavior in patients with T2D compared with insulin treatment alone [28,29], which might be beneficial to improving endothelial dysfunction. This evidence concerns the gene GCG and endothelial dysfunction.